Opinion|Videos|January 2, 2025

Overview of Port Delivery System With Ranibizumab

Panelists discuss how the port delivery system (PDS) is a permanent, refillable ocular implant that continuously releases ranibizumab into the vitreous, with the Archway trial demonstrating noninferior vision outcomes compared with monthly ranibizumab injections while reducing treatment burden through 6-month refill intervals.

Video content above is prompted by the following:

  • Can you provide an overview of the PDS with ranibizumab approved for treating neovascular age-related macular degeneration?
  • How does the device function?
  • Could you discuss the key outcomes from the Archway trial for PDS?

Latest CME